Prenetics Global Limited
$18.2
▲
0.56%
2026-04-21 08:56:00
www.prenetics.com
NGM: PRE
Explore Prenetics Global Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$300.05 M
Current Price
$18.2
52W High / Low
$23.63 / $3.84
Stock P/E
—
Book Value
$10.89
Dividend Yield
—
ROCE
-28.75%
ROE
-31.79%
Face Value
—
EPS
$-3.79
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
—
Beta
0.27
Debt / Equity
1.01
Current Ratio
3.01
Quick Ratio
2.18
Forward P/E
-26.07
Price / Sales
3.24
Enterprise Value
$212.62 M
EV / EBITDA
-6.45
EV / Revenue
2.3
Rating
Strong Buy
Target Price
$31.25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ICON Public Limited Company | $114.42 | 15.51 | $8.76 B | — | 8.66% | 6.27% | $211 / $66.57 | $122.25 |
| 2. | Veracyte, Inc. | $33.45 | 39.66 | $2.63 B | — | 5.82% | 5.34% | $50.71 / $22.61 | $16.5 |
| 3. | Agilent Technologies, Inc. | $122.3 | 26.99 | $34.7 B | 0.84% | 14.25% | 19.95% | $160.27 / $99.12 | $24.44 |
| 4. | Advanced Biomed Inc. | $5 | 1.49 | $6.55 M | — | — | 80.18% | $48.8 / $3.61 | $8.76 |
| 5. | Inotiv, Inc. | $0.29 | — | $9.46 M | — | -17.26% | -49.76% | $3.32 / $0.22 | $3.17 |
| 6. | Quest Diagnostics Incorporated | $200.41 | 22.15 | $22.16 B | 1.76% | 11.16% | 14.75% | $213.5 / $160.02 | $65.18 |
| 7. | iSpecimen Inc. | $0.13 | — | $4.05 M | — | -355.55% | -3.28% | $3.18 / $0.1 | $0.31 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 23.55 M | 17.68 M | 17.31 M | 10.49 M | 3.53 M |
| Operating Profit | -6.56 M | -9.87 M | -10.94 M | -17.86 M | -9.35 M |
| Net Profit | -7.41 M | -12.41 M | -10.39 M | -16.34 M | -10.67 M |
| EPS in Rs | -0.48 | -0.81 | -0.68 | -1.07 | -0.7 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 30.62 M | 21.74 M | 13.16 M | 12.53 M |
| Operating Profit | -50.89 M | -52.41 M | -65.92 M | -56.45 M |
| Net Profit | -46.3 M | -62.72 M | -190.45 M | -174.01 M |
| EPS in Rs | -3.03 | -4.1 | -12.45 | -11.38 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 213.57 M | 254.17 M | 312.13 M | 148.51 M |
| Total Liabilities | 42.23 M | 44.01 M | 68.67 M | 549.4 M |
| Equity | 170.39 M | 206.36 M | 237.06 M | -400.81 M |
| Current Assets | 86.15 M | 93.66 M | 241.81 M | 106.89 M |
| Current Liabilities | 36.55 M | 39.48 M | 57.2 M | 58.74 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -28.87 M | -13.77 M | 14.52 M | 13.42 M |
| Investing CF | 38.54 M | -82.95 M | -46.15 M | -22.02 M |
| Financing CF | -3.34 M | -4.7 M | 143.32 M | 29.32 M |
| Free CF | -29.94 M | -14.68 M | 8.17 M | 2 M |
| Capex | -1.06 M | -0.91 M | -6.34 M | -11.41 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 40.83% | 65.17% | 5.04% | — |
| Earnings Growth % | 26.18% | 67.07% | -9.45% | — |
| Profit Margin % | -151.22% | -288.48% | -1446.78% | -1388.44% |
| Operating Margin % | -166.19% | -241.02% | -500.74% | -450.43% |
| Gross Margin % | 50.29% | 40.61% | 27.48% | 28.75% |
| EBITDA Margin % | -168.41% | -224.23% | -1656.31% | -1668.95% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-11-14 | 1:0.0666667 |
| 2022-05-18 | 1:1.29 |